Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novartis starts phase III trial for osteoarthritis drug
The calcitonin to be used in the study was produced by Novartis using Unigene Laboratories’ patented manufacturing process, and Unigene will receive royalty payments if the product is
The calcitonin to be used in the study was produced by Novartis using Unigene Laboratories’ patented manufacturing process, and Unigene will receive royalty payments if the product is
Sartorius will use Crucell’s key technology to evaluate monoclonal antibodies produced using PER.C6 cells for calibrating and testing equipment products useful in the manufacture and/or purification of recombinant
According to the companies, in the international phase III trial, the survival of those patients receiving Nexavar was extended by 44%, or approximately three months, compared to those
Corautus Genetics is a development-stage company dedicated to the development of innovative products across various indications. VIA Pharmaceuticals, meanwhile, is focused on cardiovascular disease, and is building a
This regimen (tositumomab and iodine I-131 tositumomab) was found to induce durable clinical and molecular remissions in patients with the disease. Specifically, researchers reported that patients who received
The company highlighted several oncology compounds that are currently in phase III trials, as well as additional compounds expected to advance into phase III trials in the next
Two randomized, controlled phase III studies evaluated four cycles of doxorubicin and cyclophosphamide followed by paclitaxel, either every three weeks or weekly for 12 weeks, compared with the
In January 2007, Can-Fite announced the enrollment of about 250 patients in a phase IIb rheumatoid arthritis (RA) clinical trial in the US, Europe and Israel, in which
The single-arm trial will enroll approximately 100 patients in Canada who will be treated with irinotecan plus nimotuzumab. Equal cohorts investigating two dosing schedules will be enrolled. Recruitment
The patent litigation had been initiated in May 2006 when Lilly sued Barr seeking to protect its Prozac Weekly product, which is indicated for the continuation treatment phase